Institute of Hematology & Blood Diseases Hospital, China: Purpura, Thrombocytopenic, Idiopathic trials

The registry lists 35 Purpura, Thrombocytopenic, Idiopathic studies with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor. 28 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 23Phase 3 2Phase 4 4No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune ThrombocytopeniaRecruitingNCT07788456Phase 4
• Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITPNot yet recruitingNCT07687134Phase 2
• rhTPO Dose Escalation vs Eltrombopag Switch in ITPNot yet recruitingNCT07476846Not applicable
• Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)RecruitingNCT07362238Phase 2
• Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)RecruitingNCT07362199Phase 2
• Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)RecruitingNCT07297563Phase 2
• Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune ThrombocytopeniaNot yet recruitingNCT07278908Phase 2/3
• National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Primary Immune Thrombocytopenia (ITP) PatientsNot yet recruitingNCT07268898
• Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)RecruitingNCT07234019Phase 2
• A Study of CD19 UCAR-T Cells in Subjects With Autoimmune DiseasesNot yet recruitingNCT07212322Not applicable
• Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)RecruitingNCT07063199Phase 2
• Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional TrialRecruitingNCT06992128Phase 2
• Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)RecruitingNCT06838962Phase 2
• An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune ThrombocytopeniaRecruitingNCT06799611Phase 2
• A Clinical Study of NAD in the Treatment of Immune ThrombocytopeniaRecruitingNCT06776510Phase 1/2
• A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITPRecruitingNCT06658834Phase 2
• Avatrombopag in the Treatment of Pediatric Immune ThrombocytopeniaRecruitingNCT06281327Phase 2
• Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)RecruitingNCT06168851Phase 2
• Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)RecruitingNCT06107582
• A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)RecruitingNCT06094881Phase 2
• A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune ThrombocytopeniaRecruitingNCT05995054Phase 2
• TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)RecruitingNCT05718856Phase 4
• A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune ThrombocytopeniaRecruitingNCT05214391Phase 2
• Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With AutoantibodiesRecruitingNCT04993885Phase 2
• TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With AutoantibodiesRecruitingNCT04915482Phase 2/3
• TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 YearsRecruitingNCT04890041Not applicable
• Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in AdultsRecruitingNCT04518475Phase 4
• Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia PatientsRecruitingNCT03998059
• Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)CompletedNCT06287567Phase 2
• A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune ThrombocytopeniaActive, not recruitingNCT06199089Phase 2
• A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune ThrombocytopeniaCompletedNCT05694767Phase 2
• A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP PtsCompletedNCT05583838Phase 4
• A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune ThrombocytopeniaActive, not recruitingNCT05562882Phase 2
• Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune ThrombocytopeniaCompletedNCT04014166Not applicable
• Low-dose Rituximab Regimens in Chinese Adult Patients With Immune ThrombocytopeniaCompletedNCT01719692Not applicable